R. Samigullina

发表

The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)

A. Baranov, V. N. Amirjanova, A. Karateev, 2021, Rheumatology Science and Practice.

Pathogenetic significance of the use of a humanized monoclonal antibody to the IL-6-α receptor (tocilizumab) in the treatment of immuno-inflammatory diseases

R. Samigullina, I. Belyaeva, A. Chudinov, 2020, Meditsinskiy sovet = Medical Council.

ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)

A. Baranov, V. Mazurov, R. Samigullina, 2020, Rheumatology Science and Practice.

Are the goals of therapy achievable in patients with rheumatoid arthritis receiving upadacitinib in real clinical practice?

A. Baranov, V. N. Amirjanova, A. Karateev, 2022, Rheumatology Science and Practice.

Etanercept in axial spondyloarthritis – treatment efficacy

R. Samigullina, I. Gaydukova, A. Chudinov, 2022, Rheumatology Science and Practice.

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis

R. Samigullina, E. Vasilenko, A. Dadalova, 2020, Modern Rheumatology Journal.

AB0712 THE INCIDENCE OF SARS-СOV-2 INFECTION IN PATIENTS WITH RHEUMATIC DISEASES ON THERAPY BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS

V. Mazurov, R. Samigullina, E. Vasilenko, 2021 .

Treatment of resistant forms of systemic lupus erythematosus with a type I interferon inhibitor in the early access program

V. Mazurov, R. Samigullina, I. Leineman, 2023, Modern Rheumatology Journal.

THU0206 А VERY EARLY (7-28 DAYS) RESPONSE ON JAK INHIBITOR TOFACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: EFFECT ON PAIN AND CENTRAL SENSITIZATION.

R. Samigullina, N. Lapkina, E. Nasonov, 2020 .

Experience with type I interferon inhibitor in systemic lupus erythematosus

V. Mazurov, R. Samigullina, I. Gaidukova, 2022, Modern Rheumatology Journal.